Where Myths Go to Die
From the Editor-in-Chief, Evidence-Based Oncology, August 2020.
Partnership to Find Patients With NRG1 Fusions for Zenocutuzumab Trial in Pancreatic Cancer
An agreement will tap Caris Life Sciences' next-generation sequencing technology to identify patients for Merus’ phase 1/2 eNRGy trial.
FDA Actions Include Third CAR T-cell Therapy
Evidence-Based Oncology regulatory updates for August 2020 feature coverage of Kite Pharma's new CAR T-cell therapy and selinexor in DLBCL.
Best Cancer Tests Don't Reach All Who Need Them
Evidence-Based Oncology managed care updates for August 2020 feature coverage of liquid biopsies, companion diagnostics, and CAR T-cell therapy.
Choice Is Vital to Biosimilar Savings Picture, Panelists Say
The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
Fewer off-target effects mean second-generation BTK inhibitors offer less cardiotoxicity and allow patients to stay on them longer, increasing their efficacy.
Rethinking Downside Risk Protection Amid Growth in Precision Medicine
Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.
Sidebar: CMS Seeks to Fix Medicaid Best-Price Barriers in Value-Based Contracting for High-Cost Therapies in Medicaid
Proposed CMS rules would make it easier for state Medicaid programs to smooth the way for value-based contracts for high-cost gene therapies.
MRD, Biomarkers in Multiple Myeloma
Clinical updates for August 2020 featured in Evidence-Based Oncology.
How DNA Medicines Could Transform Treatment of Glioblastoma Multiforme
Better technology is rekindling the promise of DNA medicines in oncology, including the treatment of glioblastoma.
Hospitals Vow to Fight Court of Appeals 340B Ruling
The ruling reversed a lower court ruling regarding the drug discount program for hospitals that serve patients covered by Medicaid.
Tafasitamab Combination Approved for Adults With R/R DLBCL
A new treatment option is approved for patients with a common form of non-Hodgkin lymphoma who cannot have an autologous stem cell transplant.
Don't Delay Cancer Care During COVID-19 Crisis
Federal and state officials have implemented policies and safeguards to slow transmission of the virus. Most troubling were state moratoriums on “elective” surgical procedures.
